- published: 01 Aug 2012
- views: 398
- author: EdirectTV
5:45
ViroPharma
ViroPharma is an international biopharmaceutical company committed to developing and comme...
published: 01 Aug 2012
author: EdirectTV
ViroPharma
ViroPharma
ViroPharma is an international biopharmaceutical company committed to developing and commercialising innovative products that address unmet medical needs. Se...- published: 01 Aug 2012
- views: 398
- author: EdirectTV
3:18
Shire/ViroPharma Deal Just The Start
Shire's purchase of ViroPharma is a signal of deals and higher prices ahead, says Jason Ko...
published: 11 Nov 2013
Shire/ViroPharma Deal Just The Start
Shire/ViroPharma Deal Just The Start
Shire's purchase of ViroPharma is a signal of deals and higher prices ahead, says Jason Kolbert, Sr. Research Analyst at the Maxim Group. http://www.thestreet.com/video/12104654/shire-deal-just-the-start.html Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet- published: 11 Nov 2013
- views: 9
1:30
ViroPharma CFFO Up 17.5%- Global Financial News Minute with Donald Baillargeon
Cash Flow from Operations for ViroPharma, Inc. for its quarter ended September 30th was $5...
published: 03 Mar 2012
author: Stocktrendnews
ViroPharma CFFO Up 17.5%- Global Financial News Minute with Donald Baillargeon
ViroPharma CFFO Up 17.5%- Global Financial News Minute with Donald Baillargeon
Cash Flow from Operations for ViroPharma, Inc. for its quarter ended September 30th was $53.1 million, a 17.5% increase over the year earlier same quarter. V...- published: 03 Mar 2012
- views: 27
- author: Stocktrendnews
2:19
ViroPharma receives FDA approval of Cinryze (C1 esterase inhibitor [human]) industrial scale manufac
http://www.StockMarketFunding.com ViroPharma receives FDA approval of Cinryze (C1 esterase...
published: 06 Aug 2012
ViroPharma receives FDA approval of Cinryze (C1 esterase inhibitor [human]) industrial scale manufac
ViroPharma receives FDA approval of Cinryze (C1 esterase inhibitor [human]) industrial scale manufac
http://www.StockMarketFunding.com ViroPharma receives FDA approval of Cinryze (C1 esterase inhibitor [human]) industrial scale manufacturing. Please like, sh...- published: 06 Aug 2012
- views: 75
- author: StockMarketFunding Trading School
0:36
Medidata Solutions Extends Enterprise Contract with ViroPharma
Medidata Solutions (MDSO) announced today that ViroPharma (VPHM) has extended its agreemen...
published: 17 Mar 2011
author: TradeTheTrend
Medidata Solutions Extends Enterprise Contract with ViroPharma
Medidata Solutions Extends Enterprise Contract with ViroPharma
Medidata Solutions (MDSO) announced today that ViroPharma (VPHM) has extended its agreement to use the Medidata Rave electronic data capture (EDC) and clinic...- published: 17 Mar 2011
- views: 306
- author: TradeTheTrend
1:25
ViroPharma Bought For 4.2 Billion Dollars
UK-listed drug company Shire has agreed to buy the US's ViroPharma - a rare disease biopha...
published: 11 Nov 2013
ViroPharma Bought For 4.2 Billion Dollars
ViroPharma Bought For 4.2 Billion Dollars
UK-listed drug company Shire has agreed to buy the US's ViroPharma - a rare disease biopharmaceutical firm - for about $4.2bn (£2.6bn). Shire will pay $50 for each ViroPharma share - a 27% premium on Friday's closing price. The US firm makes drug Cinryze for the treatment of Hereditary Angioedema (HAE), a genetic immune disorder. Shire shares were up 1.65% in London trade. Shire is registered in Jersey and its HQ is in the Irish Republic. "The acquisition of ViroPharma will immediately benefit Shire and is entirely consistent with our clear strategic objective of strengthening our rare disease portfolio," said Shire chief executive Flemming Ornskov. "It brings us a new growth-driving product which augments our already strong growth prospects." He added: "Shire is also excited by the prospect of being able to offer two complementary treatments, Firazyr for the treatment of acute HAE attacks and Cinryze for prophylactic treatment of patients suffering from HAE." The firm envisages cost savings of $150m by 2015 from the deal, which it says will create a unit with revenues of $2bn a year. Drugs that treat rare diseases are being increasingly targeted by firms that are losing patent protection on their more conventional drug lines.- published: 11 Nov 2013
- views: 0
0:51
ViroPharma Up 2% as Q4 Profit Triples, Tops Street
ViroPharma (VPHM) is up 2.43% to $16.43, on positive 2010 Q4 results. The biotech company'...
published: 24 Feb 2011
author: FinancialNewsOnline
ViroPharma Up 2% as Q4 Profit Triples, Tops Street
ViroPharma Up 2% as Q4 Profit Triples, Tops Street
ViroPharma (VPHM) is up 2.43% to $16.43, on positive 2010 Q4 results. The biotech company's quarterly profit tripled on increased sales of Cinryze and Vancocin. The company reported net income...- published: 24 Feb 2011
- views: 25
- author: FinancialNewsOnline
7:07
Training video for administration
...
published: 11 Jul 2012
author: SeizuresBuccolam
Training video for administration
8:25
Agiloft Contract Managment Software Demonstration
http://www.agiloft.com/contract-management.htm - This video demonstrates Agiloft's Contrac...
published: 24 Oct 2013
Agiloft Contract Managment Software Demonstration
Agiloft Contract Managment Software Demonstration
http://www.agiloft.com/contract-management.htm - This video demonstrates Agiloft's Contract Management Software platform.- published: 24 Oct 2013
- views: 1
2:41
Shire goes Viro
Shire is bolstering its rare diseases drug portfolio with a $4.2bn acquisition of ViroPhar...
published: 11 Nov 2013
Shire goes Viro
Shire goes Viro
Shire is bolstering its rare diseases drug portfolio with a $4.2bn acquisition of ViroPharma. Lex's Nikki Tait and Vincent Boland discuss how this big buy fits with the pharmaceuticals company's cost drive. For more video content from the Financial Times, visit http://www.FT.com/video Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k Twitter https://twitter.com/ftvideo Facebook https://www.facebook.com/financialtimes- published: 11 Nov 2013
- views: 7
0:16
2012 Manny Award Nominee: Cinryze EU
A short intro for the 2012 Manny nominee for Best Professional Advertising Campaign for Vi...
published: 13 Apr 2012
author: DudnykHealth
2012 Manny Award Nominee: Cinryze EU
2012 Manny Award Nominee: Cinryze EU
A short intro for the 2012 Manny nominee for Best Professional Advertising Campaign for ViroPharma's Cinryze.- published: 13 Apr 2012
- views: 157
- author: DudnykHealth
2:59
Upbeat China Data Kickstarts Week
Upbeat economic data from China, including industrial production rising 10.3% and retail s...
published: 11 Nov 2013
Upbeat China Data Kickstarts Week
Upbeat China Data Kickstarts Week
Upbeat economic data from China, including industrial production rising 10.3% and retail sales up 13.3%, keep futures flat in the US ahead of the week's trading. Shire acquires Viropharma for $4.2 billion to increase their rare disease portfolio. Annual cost synergies of $150 million are expected by 2015. Transocean increases their dividend to $3 per share after releasing earnings last week. The company will also create an MLP and set a cost savings target of $500 million by 2015. TheStreet's Joe Deaux and Nicole Urken report in New York. http://www.thestreet.com/video/12103897/upbeat-china-data-kickstarts-week.html Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet- published: 11 Nov 2013
- views: 126
5:46
Light Volume Trading Expected On Veterans Day Holiday
This morning, the S&P; 500 Index e-mini futures (ES-Z3) are trading higher by just 0.75 poi...
published: 11 Nov 2013
Light Volume Trading Expected On Veterans Day Holiday
Light Volume Trading Expected On Veterans Day Holiday
This morning, the S&P; 500 Index e-mini futures (ES-Z3) are trading higher by just 0.75 points to 1766.75 per contract. Traders should note that the bond market is closed for the Veterans Day holiday. Generally, the trading volume should be very light today. Traders should watch for early action in some of the biotech stocks. Earlier today, ViroPharma Inc. (NASDAQ:VPHM) was acquired by U.K. biopharmaceutical firm Shire PLC. (NASDAQ: SHPG) for $50.00 a share.- published: 11 Nov 2013
- views: 104
4:35
14th Annual Dash for Organ & Tissue Donor Awareness
On April 19th 2009, transplant and hospital professionals, organ transplant recipients and...
published: 29 May 2009
author: giftoflife1
14th Annual Dash for Organ & Tissue Donor Awareness
14th Annual Dash for Organ & Tissue Donor Awareness
On April 19th 2009, transplant and hospital professionals, organ transplant recipients and families, living donors and recipients, donor family and friends c...- published: 29 May 2009
- views: 794
- author: giftoflife1
Youtube results:
5:51
WDR WTI VPHM Stock Analysis Video
Stock Analysis Video WDR - Waddell & Reed WTI - W&T; Offshore, Inc. VPHM - Viropharma, Inc....
published: 07 Aug 2011
author: MajesticTrader
WDR WTI VPHM Stock Analysis Video
WDR WTI VPHM Stock Analysis Video
Stock Analysis Video WDR - Waddell & Reed WTI - W&T; Offshore, Inc. VPHM - Viropharma, Inc. August 5th, 2011 Produced by - Ronald Lang, Senior Partner www.Maj...- published: 07 Aug 2011
- views: 25
- author: MajesticTrader
0:38
Passfail.com News: Analyst Moves: KSS, VPHM
Kohl's (KSS) was initiated today with a neutral rating by UBS (UBS) and a price target of ...
published: 11 Apr 2012
author: behindtheticker
Passfail.com News: Analyst Moves: KSS, VPHM
Passfail.com News: Analyst Moves: KSS, VPHM
Kohl's (KSS) was initiated today with a neutral rating by UBS (UBS) and a price target of $53, as the firm believes that the company needs a change in its ca...- published: 11 Apr 2012
- views: 10
- author: behindtheticker
11:27
Oodles of Biotechs
Trubion's new arthritis drug * CVTX's Grand Slam * Viropharma gets FDA approval * Ariad di...
published: 17 Nov 2008
author: wallstreetmedia
Oodles of Biotechs
Oodles of Biotechs
Trubion's new arthritis drug * CVTX's Grand Slam * Viropharma gets FDA approval * Ariad discusses Phase III program for scarcoma.- published: 17 Nov 2008
- views: 66
- author: wallstreetmedia
0:54
20nine would like to thank...
20nine recently accepted a Pepperpot Award for collaborating with ViroPharma on their 2010...
published: 21 Dec 2010
author: follow20nine
20nine would like to thank...
20nine would like to thank...
20nine recently accepted a Pepperpot Award for collaborating with ViroPharma on their 2010 annual report, Unsung Heros. This is our acceptance video.- published: 21 Dec 2010
- views: 167
- author: follow20nine